Study finds sizable delay in use of new antibiotics

It's no secret that the landscape for developing new antibiotics poses many obstacles for drug companies, both scientific and financial.

To begin with, finding substances with novel mechanisms to combat bacterial pathogens is challenging and expensive. When scientists do identify a promising antibacterial candidate, the subsequent path to regulatory approval of new drugs is long and winding. Then, once these drugs are on the mar